Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 2/20 | 0.33 |
| ▸ | PTGES | O14684 | 4/20 | 0.33 |
| ▸ | EP300 | Q09472 | 2/20 | 0.32 |
| ▸ | MTOR | P42345 | 5/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.32 |
| ▸ | FEN1 | P39748 | 2/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.31 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5037661 | 1.00 | F10 (0.50) | F10PDPK1VNN1PTGESEP300 | |
| SCHEMBL5040624 | 0.85 | F10 (0.56) | F10VNN1MGLL | |
| SCHEMBL5040640 | 0.85 | F10 (0.56) | F10VNN1MGLL | |
| Acetic Acid SCHEMBL5040924 | 0.84 | F10 (0.64) | F10PTGESALOX5APFEN1 | |
| SCHEMBL5043086 | 0.83 | PDPK1 (0.37) | F10PDPK1VNN1EP300MTOR | |
| SCHEMBL5043089 | 0.83 | PDPK1 (0.37) | F10PDPK1VNN1EP300MTOR | |
| SCHEMBL5042112 | 0.80 | F10 (0.77) | F10 | |
| SCHEMBL5042821 | 0.75 | F10 (0.47) | F10PDPK1 | |
| SCHEMBL5045474 | 0.75 | F10 (0.45) | F10 | |
| SCHEMBL5038731 | 0.75 | F10 (0.45) | F10ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | F10 8/4885PDPK1 3645/4885VNN1 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.